NCT00972595View on ClinicalTrials.gov

Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106)

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

August 31, 2004

Study Completion Date

September 30, 2004

Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
DRUG

ondansetron clinical trial formulation

Single dose of an over-encapsulated 8 mg tablet of United Kingdom (U.K.) ondansetron (ZOFRAN™) in one of two treatment periods.

DRUG

ondansetron marketed formulation

Single dose of an 8 mg tablet of U.K. ondansetron (ZOFRAN™) in one of two treatment periods.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00972595 - Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106) | Biotech Hunter | Biotech Hunter